Actxa Pte Ltd ('Actxa'), a deep tech company from Singapore specializing in AI, has signed a Memorandum of Understanding (MOU) with the Diabetes and Hypertension Clinic ('DHC') in India, a center dedicated to diabetes evaluation and management. This MOU, signed on June 6, 2024, signifies a strategic move for Actxa to advance research on diabetes prevention using artificial intelligence ('AI') in India.
Since 2017, Actxa has been working with research and medical institutions in Singapore to develop non-invasive technology for detecting elevated blood glucose levels and assessing diabetic risk. The company completed its first clinical trial in 2022 and published its first scientific paper in 2023. Actxa's BGEM is the world's first non-invasive blood glucose monitoring solution, powered by an AI-driven algorithm that allows wearables and hearables with Photoplethysmography (PPG) sensors to evaluate the risk of impaired glucose regulation.
In India, approximately 77 million adults suffer from Type 2 Diabetes Mellitus (T2DM), with nearly 25 million classified as prediabetic. Individuals with diabetes face an elevated risk of severe health issues, such as heart attacks, strokes, and kidney failure. Over time, T2DM can damage blood vessels in the heart, eyes, kidneys, and nerves. This MOU aims to expand the research on non-invasive blood glucose monitoring using artificial intelligence within the Indian population. If successful, the non-invasive solution will offer an affordable and user-friendly method to encourage regular monitoring of blood glucose levels and diabetic risk in India.
Marcus Soo, Actxa's Chief Executive Officer, said, “We are happy to work with like-minded professionals like Dr. Abhinav Gupta of DHC. This collaboration showcases commitment from both Actxa and DHC and our dedication to improving the lives of individuals affected by diabetes through innovation and excellence using advanced science and AI technology. Together with DHC, we aim to empower individuals in India with valuable insights into their diabetic health.”
Dr. Abhinav Gupta, MBBS, MD, FRCP, Professor of Medicine at ASCOMS, shared, “Our collaboration with Actxa represents a pivotal milestone in our journey in advancing diabetes prevention and care. Through research on AI-based algorithms for detecting hyperglycemia in diabetes patients, we are poised to make significant strides in early detection and treatment. This partnership underscores our dedication to harnessing cutting-edge technology for better health outcomes, aligning with the innovative BGEM technology.”
Headquartered in Singapore, Actxa Pte Ltd is a deep tech company founded in 2015 that leverages artificial intelligence to create next-generation preventive healthcare solutions. The company focuses on providing evidence-based, personalized health insights in the areas of physical activities, sleep quality, body composition, stress and recovery, heart health, and blood glucose evaluation and monitoring. To enhance population health, Actxa forms worldwide partnerships and engages in research collaborations, aiming to develop critical preventive health models that help individuals avert chronic diseases such as diabetes and hypertension.